No More Tears

Image source:

What's going on?

Dry your eyes, Johnson & Johnson: the pharmaceutical giant announced better-than-expected quarterly earnings on Wednesday.

What does this mean?

Both Johnson & Johnson’s (J&J’s) revenue and profit beat investors’ expectations, rising 27% and 73% respectively from the same time last year. More than half that revenue growth came from a strong rebound in the company’s medical devices unit, which took a thumping last year as the pandemic forced hospitals to postpone surgeries.

J&J’s pharmaceutical segment – the biggest of its businesses – should be getting a boost too: the pharma giant said it was expecting $2.5 billion in sales from its single-shot vaccine in 2021. That’d be a remarkably strong finish to the year given that the vaccine only generated $164 million last quarter, but the company’s gone all in on the estimate: it upped its growth outlook for both its total revenue and profit this year.

Why should I care?

For markets: Repeat after us: cancer bad.
Curing coronavirus is both ethically responsible and commercially shrewd, sure, but J&J would do well to remember that giving people cancer isn’t: the company recently had to recall its sunscreens after they were found to be contaminated with a carcinogen. And the last thing J&J needs is another fine, with the company already expected to reach an agreement to pay $5 billion to different US states over its role in the opioid crisis.

The bigger picture: Delta’s your captain now.
J&J’s anticipated $2.5 billion in sales is a drop in the ocean compared to how much Pfizer and Moderna’s shots – which are in much wider use – are expected to make. And even that revenue stream could be derailed if US production troubles keep hobbling the vaccine’s rollout, or if the highly contagious delta variant – now dominant in many countries around the world – ends up reducing the shot’s effectiveness, as plenty of experts are worried it’ll do.

Originally posted as part of the Finimize daily email.

The top 2 financial news stories in 3 minutes. Join over one million Finimizers

Read next

Spin The Bottle

Sign up to Finimize

Get the two most important global financial news stories each day. Sent at midnight UK time.

Get started with one email a day

The top financial news stories in 3 minutes.